- Home
- RCS vs INBX Comparison
RCS vs INBX Comparison
Compare RCS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- INBX
- Stock Information
- Founded
- RCS 1994
- INBX 2010
- Country
- RCS United States
- INBX United States
- Employees
- RCS N/A
- INBX N/A
- Industry
- RCS Investment Managers
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- INBX Health Care
- Exchange
- RCS Nasdaq
- INBX Nasdaq
- Market Cap
- RCS 279.8M
- INBX 237.5M
- IPO Year
- RCS N/A
- INBX 2020
- Fundamental
- Price
- RCS $7.80
- INBX $14.76
- Analyst Decision
- RCS
- INBX Hold
- Analyst Count
- RCS 0
- INBX 1
- Target Price
- RCS N/A
- INBX N/A
- AVG Volume (30 Days)
- RCS 141.1K
- INBX 115.9K
- Earning Date
- RCS 01-01-0001
- INBX 08-13-2024
- Dividend Yield
- RCS 10.12%
- INBX N/A
- EPS Growth
- RCS N/A
- INBX N/A
- EPS
- RCS N/A
- INBX 118.83
- Revenue
- RCS N/A
- INBX $1,687,000.00
- Revenue This Year
- RCS N/A
- INBX N/A
- Revenue Next Year
- RCS N/A
- INBX N/A
- P/E Ratio
- RCS N/A
- INBX $0.13
- Revenue Growth
- RCS N/A
- INBX 24.26
- 52 Week Low
- RCS $4.51
- INBX $10.80
- 52 Week High
- RCS $6.31
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- RCS 72.59
- INBX 44.24
- Support Level
- RCS $7.61
- INBX $15.11
- Resistance Level
- RCS $7.70
- INBX $15.91
- Average True Range (ATR)
- RCS 0.12
- INBX 0.64
- MACD
- RCS -0.01
- INBX -0.24
- Stochastic Oscillator
- RCS 89.36
- INBX 1.62
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.